Frazier Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Frazier Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-30	Closed	-$15.8K	–	676
2025 Q2	$15.8K	Buy	30 +6	+25%	+$3.35K	0.01%	292
2025 Q1	$15.2K	Hold	24	–	–	0.01%	279
2024 Q4	$16.9K	Hold	24	–	–	0.01%	270
2024 Q3	$25.2K	Buy	24 +9	+60%	+$10K	0.02%	229
2024 Q2	$15.8K	Sell	15 -5	-25%	-$4.85K	0.01%	342
2024 Q1	$19.3K	Hold	20	–	–	0.02%	272
2023 Q4	$17.6K	Buy	+20	New	+$16.5K	0.02%	254

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Financial Advisors's REGN Position: Q3 2025 in Review

Frazier Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 30 shares — an estimated $15.8K sold.

Frazier Financial Advisors first reported a position in REGN in Q4 2023 and held it in 7 quarters. The position peaked at $25.2K in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Frazier Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Frazier Financial Advisors sold 30 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $15.8K.
Frazier Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 7 quarters.
Frazier Financial Advisors's Regeneron Pharmaceuticals position peaked at $25.2K in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Frazier Financial Advisors's 13F filing for Q3 2025, filed 31 Oct 2025.